Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors inside the central nervous technique, conolidine modulates alternate molecular targets. A Science Advancements review identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availa... https://noelh986txj7.wikicorrespondence.com/user